Adenocarcinoma News and Research

RSS

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

Novartis receives FDA approval for Afinitor to treat pancreatic neuroendocrine tumors

Yesterday, the U.S. Food and Drug Administration approved the Novartis drug Afinitor for the treatment of advanced pancreatic neuroendocrine tumors.

7 May 2011

Merck receives Health Canada approval for GARDASIL to treat HPV in women upto age 45

Today, Merck announced that Health Canada has extended the indication of GARDASIL in women up to the age of 45. Merck's HPV vaccine is now approved for girls and women nine through 45 years of age for the prevention of cervical cancer, vulvar and vaginal cancers, precancerous lesions and genital warts caused by the Human Papillomavirus types 6, 11, 16, 18. Previously, GARDASIL was approved in girls and women nine through 26.

26 Apr 2011

Multipolar electrocoagulation is a safe, effective therapy for Barrett's esophagus

A new study reports that multipolar electrocoagulation in combination with acid suppression is a safe and effective method to ablate nondysplastic Barrett's esophagus over the long term.

26 Apr 2011

AIDS people may face high risk of stomach and esophageal malignancies

Among people with AIDS, the risk of stomach and esophageal malignancies is higher than among the general population, according to study results presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

5 Apr 2011

APC-300 drug significantly inhibits pancreatic cancer cell growth: Adamis

Adamis Pharmaceuticals Corporation announced today that in addition to its activity in prostate cancer, its drug APC-300 significantly inhibits the growth of pancreatic cancer cells.

25 Mar 2011

Researcher argues against use of Cop1-inhibitory drugs for cancer treatment

Jean-Christophe Marine strongly argues against the use of Cop1-inhibitory drugs. The protein Cop1 has -for a long time - been seen as an attractive drug target for cancer. But Jean-Christophe Marine found out that Cop1 acts as a tumor suppressor, and thus inhibits tumor formation. His new data will have direct implications for the development of cancer drug targets.

16 Mar 2011

Genetic variant contributes to higher risk of lung cancer, increases tendency to smoke more

Norwegian researchers have discovered genes that increase not only one's risk of lung cancer, but perhaps one's urge to smoke as well. Now these researchers are working on developing a blood test for lung cancer.

11 Mar 2011

AGA issues Medical Position Statement on Treatment of Barrett's Esophagus

BARRX Medical, Inc., a leader in developing minimally invasive medical devices to remove precancerous tissue from the gastrointestinal tract, reported today that the American Gastroenterological Association has issued the AGA Medical Position Statement on the Treatment of Barrett's Esophagus.

10 Mar 2011

BioSante vaccine increases median survival of resected pancreatic cancer patients

BioSante Pharmaceuticals, Inc. today announced publication of results from a Phase II clinical study that show BioSante's Pancreas Cancer Vaccine increased the median survival of resected pancreatic cancer patients from 15 to 20 months, as reported in published data, to 24.8 months, an increase of more than 25 percent.

4 Mar 2011

Protein serum amyloid A could be a potential diagnostic biomarker for lung cancer

Scientists are reporting discovery of a protein in the blood of lung cancer patients that could be used in a test for the disease - difficult to diagnose in its earliest and most treatable stages - and to develop drugs that stop lung cancer from spreading. Their study appears in ACS's Journal of Proteome Research.

3 Mar 2011

Additional pathology tests can improve survival rates in patients with oesophageal cancer

A University of Adelaide medical researcher says current treatment for people diagnosed with oesophageal cancer could be improved with additional pathology tests.

2 Mar 2011

New study: Enzyme that metabolizes vitamin D can predict lung cancer survival

Recent research suggests vitamin D may be able to stop or prevent cancer. Now, a new study finds an enzyme that plays a role in metabolizing vitamin D can predict lung cancer survival.

1 Mar 2011

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that encouraging preliminary results of a Phase 2 trial of ganetespib as a single agent in non-small cell lung cancer were presented at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

27 Feb 2011

New rapid and inexpensive test can effectively identify never-smoking group with lung adenocarcinoma

An inexpensive and rapid testing method can effectively identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence, US researchers have found.

25 Feb 2011

American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer

Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

23 Feb 2011

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has signed a licensing agreement with Biocare Medical, a biotechnology company based in Concord, Calif., for the exclusive worldwide sales and distribution rights for the immunohistochemistry of an antibody designed to detect tumor prevalence in prostate cancer patients.

18 Feb 2011

Scientists to present research on RMI ability to classify lung, kidney tumors at USCAP meeting

Clinical researchers from Cornell Weil Medical School and University of Chicago Medical School will present research conducted on Raman Molecular Imaging's ability to differentiate diagnostic dilemmas in lung and kidney tumors at the United States and Canadian Academy of Pathology's 100th Annual Meeting, Feb. 26-March 4 at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

16 Feb 2011

Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint

Oncolytics Biotech Inc. today announced preliminary results from a U.S. Phase 2 clinical trial (REO 017) using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar®) in patients with advanced pancreatic cancer. The trial is being conducted at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio (CTRC).

15 Feb 2011

Everolimus phase III study shows improved progression-free survival in patients with pNET

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin, has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Feb 2011

American Cancer Society reports racial disparity continues to increase death rate for some cancers

While the overall death rate for cancer continues to drop among African Americans, the group continues to have higher death rates and shorter survival of any racial and ethnic group in the U.S. for most cancers. The findings come from Cancer Facts & Figures for African Americans 2011-2012, the latest edition of a report produced every two years by the American Cancer Society.

1 Feb 2011